Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03859843
Recruitment Status : Not yet recruiting
First Posted : March 1, 2019
Last Update Posted : March 5, 2019
Sponsor:
Information provided by (Responsible Party):
Hiba A H alshaaby, Assiut University

Brief Summary:
Efficacy and Antimicrobial activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A randomized controlled trial

Condition or disease Intervention/treatment Phase
Platelet-Rich Plasma Acne Vulgaris Combination Product: PRP Other: Chemical peeling (Salycilic acid) Other: Chemical peeling (Jessener's solution) Phase 3

Detailed Description:

Acne vulgaris is one of the most common chronic skin diseases worldwide. The condition usually starts in adolescence, peaks at the ages of 14 to 19 years and frequently resolves by mid-twenties.

Acne is characterized by seborrhea, formation of open and closed comedones, erythematous papules and pustules and in more severe cases present with nodules, deep pustules and pseudo cysts, in many cases a degree of scarring will ensue.

Its pathophysiology includes hyperseborrhoea, abnormal follicular keratinization and Propionibacterium acnes proliferation in the pilosebaceous unit.

Acne is a significant clinical problem with sever social, psychological, and emotional implications. A mainly genetically determined host response pattern combined with bacterial ''triggering'' is generally accepted as being important for the apparently unbalanced inflammatory activity.

Acne is not an infectious disease, but three major organisms were isolated from the surface of the skin and the pilosebaceous duct of patients with acne including Propionibacterium acne, Staphylococcus epidermidis and Malassezia furfur.

Platelet rich plasma is a good choice for the treatment of acne and atrophic scars reminiscent of the course of the disease. In addition, for being autologous, it reduces the possibility of side effects, such as skin dryness and rejection.

It was demonstrated that PRP accelerates the healing process, regulates inflammation and promotes healing by inhibiting the P. acnes bacteria, additionally restoring collagen). The PRP's mechanism of action also involves the release of powerful antimicrobial peptides from the platelets' alpha granules.

Although there are few studies on the PRP's effectiveness in acne, it emerges as a potential therapeutic option in Dermatology and Aesthetic Medicine.

Due to development of resistance in microorganisms causing acne to common antibiotics and differences in species and strains of the microorganisms in different regions, this study will be undertaken to determine bacteria involve in acne vulgaris and the effect of PRP on it.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy and Antimicrobial Activity of Platelet Rich Plasma (PRP) in Acne Vulgaris : A Randomized Controlled Trial
Estimated Study Start Date : January 10, 2020
Estimated Primary Completion Date : January 10, 2021
Estimated Study Completion Date : May 10, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Acne Antibiotics

Arm Intervention/treatment
Active Comparator: PRP Combination Product: PRP
Ten mL of venous blood will be drawn in a syringe fill with 1.5 mL of anticoagulant solution (anticoagulant citrate dextrose solution formula A, Baxter, Deerfield, IL). The blood will be centrifuged at 160 g for 10 minutes. After the first spin, the lower red blood cell portion will be discarded, and the supernatant will be centrifuged at 400 g for 10 minutes. The resulting pellet of platelets will be mixed with 1.5 mL of supernatant, which make 1.5 mL of PRP. One mL of 3% calcium chloride will be added to the PRP to induce platelet activation.

Active Comparator: Chemical peeling (Salycilic acid) Other: Chemical peeling (Salycilic acid)
SA is a 2-hydroxybenzoic acid (from willow tree) used for superficial peeling due to its strong keratolytic and comedo- lytic properties. It promotes shedding of epidermal cells and due to its lipophilic properties can penetrate comedones and pores to prevent clogging and neutralize bacteria. It promotes desquamation of the upper lipophilic layers of the stratum corneum.19 These chemical properties explain its popularity and success in acne patients.It also has well- documented anti-inflammatory properties.

Active Comparator: Chemical peeling (Jessenr's solution) Other: Chemical peeling (Jessener's solution)
is a superficial peeling agent used as adjuvant therapy for acne. it is generally proposed to break of the hydrogen bonds of keratin (keratolysis), disruption of cell membranes (cell death) and is bactericidal.




Primary Outcome Measures :
  1. Cure rate [ Time Frame: 3 months ]
    Assess cure rate of PRP and Chemical peeling agents in treatment of Aactive Acne Vulgaris in 3 months duration and compare efficacy of all measures



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   14 Years to 40 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with active acne vulgaris lesions (inflammatory and non-inflammatory).
  • Age range from 14 to 40 years.
  • Patients with any topical and systemic treatments will undergo wash out period of one month.

Exclusion Criteria:

  • Patients with herpes labials, or bacterial infection; warts on the face, actinic keratosis, or skin cancer or allergy to medications.
  • Systemic retinoids intake in the previous 6 months
  • History of keloidal scarring.
  • Patients on anticoagulant therapy or aspirin or have a coagulation issue,
  • Patients with hemoglobin less than 10g\dl or platelet less than 105 micron\l
  • Pregnant women
  • Immunocompromised patients
  • Patients with medical diseases like diabetes mellitus, epilepsy or malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03859843


Contacts
Layout table for location contacts
Contact: Sara Awad, PhD ‭+20 102 3102094‬ saramawad@gmail.com
Contact: Yassmin Mustfa Tuwfik, Lecturer ‭00 20 100 6033331‬ dr.yasminmostuwfik@yahoo.com

Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Hiba A H alshaaby, Principal investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03859843     History of Changes
Other Study ID Numbers: PRP in Acne Vulgaris
First Posted: March 1, 2019    Key Record Dates
Last Update Posted: March 5, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Anti-Bacterial Agents
Pharmaceutical Solutions
Anti-Infective Agents